 The primary objective of the phase III clinical trial is to provide proof of concept POC that up to 10 times dose reduction of IPV SSI does not decrease the immunogenicity clinically significantly compared to full dose IPV SSI, by demonstrating the non-inferiority of the booster effects of each of 3 AlOH3 adjuvated reduced dose IPV formulations 13 IPV-Al SSI, 15 IPV-Al SSI and 110 IPV-Al SSI compared to non-adjuvated full dose IPV SSI. 